Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- RaQualia to Slim Down Its Organization Considering Spinning Off Non-Core Development Programs
November 14, 2012
- Towa: 1st Half Sales Up 16%, But Less-than Expected Benefits from Generic Name Prescriptions
November 14, 2012
- Gap between Oncology MRs and Doctors Should Be Closed: Mr Mitsuhashi of Merck Serono
November 13, 2012
- CMIC HD Forms Business Partnership with Japanese Subsidiary of Leading CSO in Europe
November 13, 2012
- Ethical Drug Sales Down 4.9% in September: Crecon Report
November 13, 2012
- Tsumura Postpones Targeted Launch for Kampo Medicine Under Development in US
November 13, 2012
- GeneDesign to Comprehensively Support Development of Nucleic Acid Medicines through New CMC Research Center: Mr Sato
November 13, 2012
- Sawai Makes Downward Revision in Full-Year Sales Forecast Despite Increases in Sales, Profits in 1st Half
November 12, 2012
- Alliance with Choseido to Increase Nihon Chouzai’s Generic Lineup to 470: President Mitsuhara
November 12, 2012
- Tsumura Aims at Sales of 123 Billion Yen in FY 2015, to Expand Kampo Market: New Mid-Term Management Plan
November 12, 2012
- Sawai Sells off All Shares of Kyorin HD Following End of Talks for Business Integration
November 12, 2012
- Kaken Aims for Approval of Japan’s 1st Topical Onychomycosis Treatment Efinaconazole Next Year
November 12, 2012
- Time Will Tell Whether Once-monthly Products Ultimately Dominate or Merely Provide Another Option in the BP Market
November 12, 2012
- Sales Increase 3.4% as Generics Make Large Gains: Kyorin HD
November 9, 2012
- Novartis Files for Approval for LABA, LAMA Combination Treatment for COPD in Japan
November 9, 2012
- 1st-Half Settlements of Top 4 Wholesalers Suggest Recovery in Operating Profit Rates in Core Drug Business
November 9, 2012
- US FDA Approves Pfizer’s Novel RA Treatment Tofacitinib
November 9, 2012
- Four Companies Discontinue Marketing Atelec Generics Due to Halt in Supplies of Bulk Drug Substance
November 9, 2012
- Sales Down by 7.8% due to Slump of Long-Listed Drugs, Transfer of Marketing Rights for Cabaser: Kissei
November 8, 2012
- Nippon Shinyaku Confident about Achieving Target in Mid-Term Management Plan Backed by Steady Growth of New Products
November 8, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…